1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,350 | 6,650 | 08:31 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | Eupraxia Pharmaceuticals Inc: Eupraxia talks improved EoE symptoms in phase 1/2 trial | 2 | Stockwatch | ||
| 13.08. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients | 300 | GlobeNewswire (Europe) | The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post... ► Artikel lesen | |
| 11.08. | Eupraxia Pharmaceuticals reports Q2 results | 1 | Seeking Alpha | ||
| 11.08. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 11.08. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results | 194 | GlobeNewswire (Europe) | New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI Strengthened executive team and board to bolster... ► Artikel lesen | |
| EUPRAXIA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 15.07. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 15.07. | Cantor Fitzgerald reiterates Eupraxia stock Overweight rating at $19 | 3 | Investing.com | ||
| 14.07. | Eupraxia Pharmaceuticals Inc: Eupraxia Pharmaceuticals appoints EVPs | 1 | Stockwatch | ||
| 13.07. | Eupraxia names new executives, relocates operations | 1 | Investing.com | ||
| 13.07. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth | 204 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen | |
| 08.07. | Eupraxia Pharmaceuticals Inc: Eupraxia Pharmaceuticals appoints three directors | 1 | Stockwatch | ||
| 07.07. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 07.07. | Eupraxia Pharmaceuticals verstärkt Verwaltungsrat mit drei Neuzugängen | 2 | Investing.com Deutsch | ||
| 07.07. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization | 332 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen | |
| 25.06. | Oppenheimer initiates Eupraxia stock with Outperform rating | 1 | Investing.com | ||
| 25.06. | Oppenheimer startet Coverage für Eupraxia mit "Outperform"-Rating und hohem Kursziel | 1 | Investing.com Deutsch | ||
| 22.06. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.06. | Eupraxia Pharmaceuticals Inc: Eupraxia shareholders approve all matters at AGM | 1 | Stockwatch | ||
| 19.06. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders | 367 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, June 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen | |
| 28.05. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings |
1 2 3 4 Weiter >>
62 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 6,532 | -0,70 % | Clinuvel Pharmaceuticals Ltd - 6-K, Report of foreign issuer | ||
| EDITAS MEDICINE | 2,820 | 0,00 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,722 | +1,06 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
20.07.2026 / 16:41 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,530 | -0,39 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from... ► Artikel lesen | |
| CYTODYN | 0,180 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,869 | -0,06 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 4,722 | -2,36 % | Emergent BioSolutions Reports Second Quarter 2026 Financial Results | Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior yearSecond Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3... ► Artikel lesen | |
| DENALI THERAPEUTICS | 21,590 | +1,08 % | DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock? | ||
| CEL-SCI | 1,170 | +8,33 % | CEL-SCI Signs Saudi Arabia Multikine Commercialization Deal With 50/50 Net Revenue Split | ||
| COHERUS ONCOLOGY | 1,176 | +0,51 % | Coherus Oncology, Inc.: Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights | - Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets - - Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company... ► Artikel lesen | |
| CURIS | 1,405 | +3,80 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| FATE THERAPEUTICS | 2,186 | 0,00 % | Fate Therapeutics, Inc.: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis | First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,977 | +3,30 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors | SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment... ► Artikel lesen | |
| FAETH THERAPEUTICS | 29,000 | -0,68 % | Needham startet Coverage für Faeth Therapeutics mit Kaufempfehlung wegen Potenzial von Krebsmedikament | ||
| CYBIN | 12,240 | +2,17 % | TD Cowen raises Helus Pharma stock price target to $62 on trial timing |
Das Unternehmen EUPRAXIA PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,250 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EUPRAXIA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.